Home About Titan Pharmaceuticals Products Press Releases Financials Resources: Scientific Articles and Presentations Contact Us

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Titan Pharmaceuticals Second Quarter 2014 Financial Results

Thursday, August 14, 2014 - 10:00am PT | 1:00pm ET

Participant Toll Free: 888-637-7707 | Participant Passcode: 8273007
THE EVENT/REGISTRATION PAGE URL FOR THE WEBCAST IS: http://www.visualwebcaster.com/event.asp?id=100256


Titan Pharmaceuticals Latest Press Releases

South San Francisco, CA – Sept. 3, 2014Titan Pharmaceuticals, Inc. (TTNP.OB), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of opioid dependence, Parkinson’s Disease, and other serious medical disorders, today announced that Titan President Sunil Bhonsle will present at the Rodman & Renshaw 16th Annual Global Investor Conference at the New York Palace Hotel in New York City on Sept. 10 from 9:35-10 a.m. The presentation will take place in the Kennedy II Salon.

Read Press Release » »

Titan Management Team to Host Conference Call Aug. 14 at 10 a.m. PT/ 1 p.m. ET

South San Francisco, CA – Aug. 13, 2014 Titan Pharmaceuticals, Inc (TTNP.OB), a specialty pharmaceutical company developing proprietary therapeutics for the treatment of opioid dependence and other serious medical disorders, today reported financial results for the second quarter ended June 30, 2014.

Read Press Release » »

South San Francisco, CA – August 7, 2014 – Titan Pharmaceuticals, Inc. (TTNP.OB) today announced that it will host a live conference call at 10 a.m. PT / 1 p.m. ET on Thursday, Aug. 14, 2014 to discuss the company’s financial results as of June 30, 2014. The call will be hosted by Sunil Bhonsle, president; Katherine Glassman-Beebe, Ph.D., executive vice president and chief development officer; Brian Crowley, vice president of finance, and Marc Rubin, M.D., executive chairman. Highlights of the second quarter and financial results will be included in a press release to be issued prior to the call.

Read Press Release » »

Study completion expected in mid-2015 followed by potential resubmission of Probuphine New Drug Application

South San Francisco, CA - July 21, 2014 - Titan Pharmaceuticals, Inc. (TTNP.OB) today announced enrollment of the first patients in the Phase 3 clinical study to support resubmission of the New Drug Application (NDA) for Probuphine®, the company’s investigational subdermal implant for the maintenance treatment of opioid dependence. The study, which is expected to be completed by the middle of 2015, is designed to address key questions posed by the U.S. Food and Drug Administration (FDA) in its complete response letter last year after review of the original NDA. Titan’s partner Braeburn Pharmaceuticals is sponsoring the trial and anticipates resubmission of the NDA to the FDA in late 2015.

Read Press Release » »

Read more Titan Pharmaceuticals Press Releases


Probuphine is Titan’s novel subdermal implant formulation designed using its ProNeura technology to deliver six months of buprenorphine hydrochloride (“buprenorphine”) following a single treatment. Probuphine is being developed for the treatment of opioid dependence...


Read More... »»


Probuphine® Program Update


June 2, 2014
Titan Provides Overview of Upcoming Study of Probuphine

Following clear guidance in late April from the FDA on the full clinical study of Probuphine®, Titan Pharmaceuticals and partner Braeburn Pharmaceuticals expect that the new clinical study will commence around mid-year, with completion anticipated in the middle of 2015.


Read More... »»


Titan Pharmaceuticals, Inc. is a biopharmaceutical Company developing proprietary therapeutics primarily for the treatment of central nervous system (“CNS”) disorders.

Titan’s principal asset is Probuphine®, the first slow-release implant formulation of buprenorphine hydrochloride (“buprenorphine”), designed to maintain a stable, round-the-clock blood level of the medicine in patients for up to six months following a single treatment. The outpatient treatment of opioid dependence with daily dosed sublingual buprenorphine formulations represents a $1.3 billion market in the U.S., and a seven day transdermal patch formulation of buprenorphine for the treatment of chronic pain was launched in the U.S. in 2011.  This novel implant formulation is inserted subdermally in a patient’s upper arm providing continuous medication...


Read more... » »